BioMarin Q1 revenue rises 3% to $766 million; profit falls 43% and EPS guidance is cut
BioMarin reported first-quarter 2026 total revenues of $766 million, up from $745 million a year earlier, while GAAP net income fell 43% to $106 million. The company raised its full-year 2026 revenue guidance to $3.825 billion to $3.925 billion, mainly reflecting the Amicus acquisition, but lowered its Non-GAAP diluted EPS guidance to $4.85 to $5.05.
Key points
- Q1 2026 GAAP net income was $106 million versus $186 million in Q1 2025; GAAP diluted EPS was $0.54 versus $0.95.
- Q1 2026 Non-GAAP diluted EPS was $0.76 versus $1.13 in the prior-year quarter.
- Full-year 2026 total revenues guidance raised to $3.825 billion to $3.925 billion from $3.325 billion to $3.425 billion; Non-GAAP diluted EPS guidance lowered to $4.85 to $5.05 from $4.95 to $5.15.
- A $31 million charge tied to an unsuccessful NAGLAZYME manufacturing process qualification campaign was recorded in cost of sales.
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.